Feedback Inhibition

Feedback inhibition is a regulatory mechanism in which the end product of a metabolic pathway inhibits an enzyme acting early in that pathway, usually the first committed step. By turning down its own production when the product accumulates, the cell avoids wasteful synthesis and keeps metabolite levels in balance.

Definition

Feedback inhibition is the regulation of a biosynthetic pathway in which its end product binds and inhibits an enzyme catalysing an early, committed step, reducing flux through the pathway as the product accumulates.

Scope

The entry covers end-product (negative feedback) inhibition as a control principle, the typical targeting of committed steps, and the allosteric basis that lets a structurally unrelated product inhibit an enzyme. It is a biochemical reference, not clinical guidance.

Core questions

• Which step in the pathway is the regulated, committed step?
• How does an end product inhibit an enzyme it does not chemically resemble?
• How does feedback inhibition keep metabolite concentrations stable?

Key concepts

• End-product (retro) inhibition
• Committed (first) step of a pathway
• Allosteric regulatory site
• Negative feedback and metabolic homeostasis
• Conformational shift on effector binding

Key theories

End-product (negative feedback) regulation

The end product of a pathway acts as an inhibitor of an early committed enzyme, so accumulation of product reduces its own synthesis; this was demonstrated for isoleucine and for pyrimidine biosynthesis and is a general principle of metabolic control.

Allosteric basis of feedback inhibition

Because the end product usually does not resemble the enzyme's substrate, it acts at a separate allosteric site; the Monod-Wyman-Changeux model explains how binding there shifts the enzyme's conformational equilibrium and lowers activity.

Mechanisms

In a biosynthetic pathway the accumulating end product binds an enzyme catalysing an early committed step and inhibits it, so that flux falls when the product is abundant and resumes when it is consumed; this negative-feedback logic was shown directly for isoleucine biosynthesis (Umbarger, 1956) and for pyrimidine biosynthesis (Yates & Pardee, 1956). Because the end product typically bears no chemical resemblance to the enzyme's substrate, it binds at a distinct allosteric site rather than the active site, and the Monod-Wyman-Changeux model accounts for how such binding shifts the enzyme between active and less-active conformations (Monod, 1965). The kinetic signature is generally that of allosteric, noncompetitive-type inhibition (Cornish-Bowden, 2012).

Clinical relevance

Feedback inhibition underlies the stability of metabolite levels, and its disruption is relevant to understanding inborn errors of metabolism and the rationale behind some metabolic interventions (Cornish-Bowden, 2012). This entry describes the regulatory principle for reference and education and does not provide diagnostic or treatment guidance.

History

Feedback inhibition was established as a regulatory principle in 1956 through nearly simultaneous reports that the end products isoleucine and pyrimidines inhibit early enzymes of their own biosynthetic pathways (Umbarger, 1956; Yates & Pardee, 1956). The allosteric model of Monod, Wyman and Changeux in 1965 then provided the structural mechanism by which a dissimilar end product can regulate an enzyme from a separate site (Monod, 1965).

Key figures

• H. Edwin Umbarger
• Arthur B. Pardee
• Jacques Monod
• Jean-Pierre Changeux

Seminal works

• umbarger-1956
• yates-pardee-1956
• monod-1965

Frequently asked questions

Why does feedback inhibition usually target the first committed step?

Inhibiting the first step that is dedicated to a pathway prevents the buildup of intermediates and avoids wasting precursors, making the control both efficient and economical.

How can an end product inhibit an enzyme it does not chemically resemble?

It binds at a separate allosteric site rather than the active site, where its binding shifts the enzyme into a less active conformation, as described by allosteric models of regulation.